0.07 | 2.33%
| Price and Volume | |
|---|---|
| Recent Price | 3.07 |
| 52 Week High | 6.86 |
| 52 Week Low | 2.34 |
| Avg. Daily Vol. (Mil) | 0.39 |
| Beta (3 year) | 1.04 |
| Share Related Items | |
| Mkt Cap (Mil) | 192.81 |
| Shares Out (Mil) | 62.80 |
| Float (Mil) | 27.48 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 11.00 |
| Current Ratio | 11.90 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 26.51 |
| Price/Book | 3.12 |
| Price/Cash Flow | -4.70 |
| Per Share Data | |
| Earnings | -0.71 |
| Sales | 0.12 |
| Book Value | 0.98 |
| Cash Flow | -0.65 |
| Business Summary | |
|---|---|
| GTx, Inc. is biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. | |
| General Information | |
| 175 Toyota Plaza
7th Floor Memphis, TN 38103 |
|
| www.gtxinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 90 | |
| CEO: Mitchell S. Steiner,M.D. | |
| Short Interest | |
| Current Month (Mil) | 2.90 |
| Previous Month (Mil) | 3.00 |
| Short Interest Ratio (Days) | 7.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -61.80 |
| Return on Investments | -67.00 |
| Profitability | |
| Gross Margin | 97.40 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet